Topic: MS

BG-12: Updated data from phase III studies

August 29, 2012  

What is the optimal dosing of natalizumab?

July 25, 2012  

Breastfeeding not a sustainable therapy

July 11, 2012  

High cost of MS in Canada

May 16, 2012  

IFN-beta in CIS: phase III REFLEX results

May 2, 2012  

Oral anti-alpha4-integrin in development

March 14, 2012  

Alemtuzumab: high rate of autoimmune disorders

December 14, 2011  

Emerging MS therapies: update on injectable drugs

November 30, 2011  

CONFIRM – Second phase III trial results for BG-12

November 30, 2011  

No benefit with simvastatin add-on therapy in MS

November 9, 2011